title: Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer.
abstract: BACKGROUND
  Although it is known that standard 5-fluorouracil-based chemoradiation therapy for rectal cancer causes significant acute gastrointestinal (GI) toxicity, research on patient-reported outcomes (PROs) is limited. The authors undertook the current study to assess the feasibility of incorporating PRO measurement into routine clinical practice and to describe the trajectory of symptom development during treatment.
  
  
  METHODS
  Seventy-seven consecutive patients who were treated between 2006 and 2008 were eligible. Patients completed the 7-item Bowel Problems Scale immediately before weekly physician visits.
  
  
  RESULTS
  The questionnaire completion rate was 95%. Individual GI symptoms had different trajectories of development. By Week 5, approximately 40% of all patients developed clinically meaningful pain, bowel urgency, or tenesmus that was not present during Week 1; 30% developed diarrhea, abdominal cramping, and passing mucus. However, overall symptom burden was moderate. Seventy-five percent of patients who presented with rectal bleeding at Week 1 improved by Week 3 of treatment. Within each physician-assessed grade of diarrhea, patient experience varied widely. For example, of the 50 patients who developed grade 2 diarrhea on the Radiation Therapy Oncology Group Acute Morbidity Scale, the numbers of patients reporting only occasional symptoms versus those reporting frequent or very frequent symptoms were similar.
  
  
  CONCLUSIONS
  PROs provided information on patient symptoms during chemoradiation treatment for rectal cancer that was not captured otherwise, and it was feasible to incorporate PROs into routine clinical practice. The current results may be used by physicians to counsel their patients before treatment initiation and to provide a benchmark against which trials that use new therapies may be compared.
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Chen
authors.forename: Harvey J
authors.initials: HJ
authors.lastname: Mamon
authors.forename: Yu-Hui
authors.initials: YH
authors.lastname: Chen
authors.forename: Rebecca S
authors.initials: RS
authors.lastname: Gelman
authors.forename: W Warren
authors.initials: WW
authors.lastname: Suh
authors.forename: James A
authors.initials: JA
authors.lastname: Talcott
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Clark
authors.forename: Theodore S
authors.initials: TS
authors.lastname: Hong
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy / Q000009:adverse effects; D003967:Diarrhea / Q000209:etiology; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D005767:Gastrointestinal Diseases / Q000209:etiology*; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010358:Patient Participation; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D005472:Fluorouracil